Ameriprise’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20M | Sell |
302,802
-243,003
| -45% | -$15.4M | ﹤0.01% | 1409 |
|
|
2025
Q4 | $34.7M | Sell |
545,805
-18,742
| -3% | -$1.17M | 0.01% | 1073 |
|
|
2025
Q3 | $31M | Buy |
564,547
+219,581
| +64% | +$9.05M | 0.01% | 1138 |
|
|
2025
Q2 | $11.4M | Sell |
344,966
-441,617
| -56% | -$15.4M | ﹤0.01% | 1715 |
|
|
2025
Q1 | $31.6M | Buy |
786,583
+34,182
| +5% | +$1.57M | 0.01% | 1058 |
|
|
2024
Q4 | $35.4M | Buy |
752,401
+210,266
| +39% | +$10.9M | 0.01% | 1025 |
|
|
2024
Q3 | $28.6M | Buy |
542,135
+198,001
| +58% | +$11M | 0.01% | 1128 |
|
|
2024
Q2 | $18.6M | Buy |
344,134
+50,111
| +17% | +$3.02M | 0.01% | 1329 |
|
|
2024
Q1 | $20.6M | Sell |
294,023
-43,232
| -13% | -$3.34M | 0.01% | 1278 |
|
|
2023
Q4 | $28.2M | Buy |
337,255
+21,837
| +7% | +$791K | 0.01% | 1077 |
|
|
2023
Q3 | $9.29M | Sell |
315,418
-29,650
| -9% | -$987K | ﹤0.01% | 1763 |
|
|
2023
Q2 | $11.3M | Sell |
345,068
-56,086
| -14% | -$2.08M | ﹤0.01% | 1670 |
|
|
2023
Q1 | $14.1M | Sell |
401,154
-16,238
| -4% | -$662K | ﹤0.01% | 1505 |
|
|
2022
Q4 | $19.1M | Sell |
417,392
-125,504
| -23% | -$5.4M | 0.01% | 1251 |
|
|
2022
Q3 | $26.3M | Sell |
542,896
-18,446
| -3% | -$888K | 0.01% | 1018 |
|
|
2022
Q2 | $22.1M | Buy |
561,342
+2,372
| +0.4% | +$95.5K | 0.01% | 1153 |
|
|
2022
Q1 | $20.6M | Sell |
558,970
-612
| -0.1% | -$21.7K | 0.01% | 1332 |
|
|
2021
Q4 | $25.5M | Buy |
559,582
+206,147
| +58% | +$7.95M | 0.01% | 1235 |
|
|
2021
Q3 | $12.6M | Buy |
353,435
+38,413
| +12% | +$1.13M | ﹤0.01% | 1656 |
|
|
2021
Q2 | $6.24M | Sell |
315,022
-1,007
| -0.3% | -$23.6K | ﹤0.01% | 2293 |
|
|
2021
Q1 | $7.35M | Buy |
316,029
+14,853
| +5% | +$317K | ﹤0.01% | 2127 |
|
|
2020
Q4 | $6.26M | Sell |
301,176
-11,447
| -4% | -$209K | ﹤0.01% | 2107 |
|
|
2020
Q3 | $6.77M | Buy |
312,623
+37,063
| +13% | +$867K | ﹤0.01% | 1860 |
|
|
2020
Q2 | $6.5M | Sell |
275,560
-33,085
| -11% | -$620K | ﹤0.01% | 1879 |
|
|
2020
Q1 | $3.64M | Sell |
308,645
-13,104
| -4% | -$167K | ﹤0.01% | 2116 |
|
|
2019
Q4 | $3.41M | Buy |
321,749
+3,714
| +1% | +$38.1K | ﹤0.01% | 2459 |
|
|
2019
Q3 | $3.62M | Sell |
318,035
-4,525
| -1% | -$56.8K | ﹤0.01% | 2384 |
|
|
2019
Q2 | $3.63M | Buy |
322,560
+11,210
| +4% | +$108K | ﹤0.01% | 2430 |
|
|
2019
Q1 | $2.52M | Buy |
311,350
+5,965
| +2% | +$43.9K | ﹤0.01% | 2631 |
|
|
2018
Q4 | $1.93M | Sell |
305,385
-7,566
| -2% | -$55.5K | ﹤0.01% | 2661 |
|
|
2018
Q3 | $3.08M | Buy |
312,951
+30,611
| +11% | +$246K | ﹤0.01% | 2631 |
|
|
2018
Q2 | $2.34M | Buy |
282,340
+18,750
| +7% | +$156K | ﹤0.01% | 2672 |
|
|
2018
Q1 | $1.9M | Buy |
263,590
+6,354
| +2% | +$54.5K | ﹤0.01% | 2704 |
|
|
2017
Q4 | $2.1M | Sell |
257,236
-101,477
| -28% | -$1.15M | ﹤0.01% | 2634 |
|
|
2017
Q3 | $5.2M | Buy |
358,713
+117,882
| +49% | +$1.61M | ﹤0.01% | 2061 |
|
|
2017
Q2 | $2.91M | Buy |
+240,831
| New | +$3.35M | ﹤0.01% | 2417 |
|
|
2016
Q2 | – | Sell |
-182,791
| Closed | -$1.29M | – | 3788 |
|
|
2016
Q1 | $1.29M | Sell |
182,791
-11,388
| -6% | -$83.2K | ﹤0.01% | 2741 |
|
|
2015
Q4 | $2.03M | Buy |
+194,179
| New | +$1.9M | ﹤0.01% | 2594 |
|
|
2015
Q3 | – | Sell |
-16,365
| Closed | -$110K | – | 3877 |
|
|
2015
Q2 | $110K | Buy |
+16,365
| New | +$107K | ﹤0.01% | 3915 |
|
|
2014
Q4 | – | Sell |
-700
| Closed | -$2K | – | 3834 |
|
|
2014
Q3 | $2K | Hold |
700
| – | – | ﹤0.01% | 5394 |
|
|
2014
Q2 | $3K | Buy |
+700
| New | +$4.27K | ﹤0.01% | 5087 |
|
|
2013
Q4 | – | Sell |
-1,654
| Closed | -$13K | – | 5194 |
|
|
2013
Q3 | $13K | Buy |
1,654
+110
| +7% | +$1.18K | ﹤0.01% | 4703 |
|
|
2013
Q2 | $18K | Buy |
+1,544
| New | +$12.2K | ﹤0.01% | 4351 |
|
Other funds holding CYTK
VPM
VCM
ACA
Ameriprise's CYTK Position: Q1 2026 in Review
Ameriprise reduced its Cytokinetics (CYTK) stake by 45% in Q1 2026, selling an estimated $15.4M and leaving 302,802 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.
Ameriprise first reported a position in CYTK in Q2 2013 and has held it in 43 quarters since. The position peaked at $35.4M in Q4 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Ameriprise held 302,802 shares of Cytokinetics worth $20M as of Q1 2026.
- Ameriprise sold 243,003 Cytokinetics shares in Q1 2026, an estimated $15.4M.
- Cytokinetics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1409 holding.
- Ameriprise first reported a position in Cytokinetics in Q2 2013 and has held it in 43 quarters since.
- Ameriprise's Cytokinetics position peaked at $35.4M in Q4 2024.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.